View Older Stories View More Recent Stories
-
Truist Securities Reiterates Hold Rating on Hims and Hers (HIMS)
-
Hims and Hers (HIMS) PT Lowered to $48 at Jefferies, 'want to see proof points of consumer traction'
-
Hims and Hers (HIMS) PT Raised to $46 at Leerink Partners
-
KeyBanc: 'Hims and Hers (HIMS) Setting the Stage for Future Growth'
-
Needham on Hims and Hers (HIMS): 'we believe this incremental near-term investment and likely growing pains'
-
Hims and Hers (HIMS) PT Raised to $32 at BofA Securities
-
BTIG Hims and Hers (HIMS): 'MAHA is being Implemented through HIMS with Proactive Health'
-
Canaccord Genuity Reiterates Buy Rating on Hims and Hers (HIMS)
-
After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina
-
Hims & Hers in talks with Novo Nordisk to offer Wegovy treatments
-
Hims & Hers Health, Inc. (HIMS) Misses Q3 EPS by 4c, Offers Guidance
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.4 calls to 1 put into quarter results
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put into quarter results
-
TD Cowen on Hims and Hers (HIMS): 'Decelerating Trends; Lack of Upside Likely'
-
KeyBanc Starts Hims and Hers (HIMS) at Sector Weight
-
Hims & Hers CEO Dudum comments on Grail investment
-
BofA: 'We maintain our Underperform rating on HIMS due to growing competition, but view this morning’s news positively'
-
Hims & Hers launches menopause treatment services
-
Hims & Hers to Offer Treatments for Menopause, Perimenopause - DJ
-
BofA Negative on Hims and Hers (HIMS): 'Lowering 4Q sales and full year below the guidance range'
-
Hims & Hers releases customer survey data on telehealth care quality
-
Hims & Hers CEO Dudum announces COO change, appointing Mike Chi
-
Hims & Hers names Mike Chi as new COO as Nader Kabbani transitions
-
BofA Reiterating Negative View on Hims and Hers (HIMS): '3Q beat less likely, order growth under more pressure'
-
Survey shows 1/3 of GLP-1 users are lower-income
-
Walmart (WMT) Adds Home Delivery for Ozempic, Other Refrigerated Drugs - Bloomberg
-
GoodRx (GDRX) Lower on Report Trump Officials Weigh Website To Help Shop For Cheaper Drugs
-
Hims & Hers Health, Inc. (HIMS) CEO Andrew Dudum: around 100 FDA letters went out last week to companies across the industry, we got one
-
FDA issues warning letter to HIMS over semaglutide marketing claims
-
CMS Launches Landmark $50 Billion Rural Health Transformation Program
-
BofA Securities on Hims and Hers (HIMS): 'Dr. Makary’s op-ed in the New York Times is a negative for HIMS'
-
Hims & Hers shares drop after FDA chief flags ad violations
-
Canaccord Genuity Positive on Hims and Hers (HIMS): 'we see several paths to FY30 targets'
-
BTIG Remains Positive Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) 'given near-term competitive pressures in the core business'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28
-
Hims and Hers (HIMS) PT Lowered to $37 at Truist Securities
-
Hims and Hers (HIMS) July orders fall further - BofA
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.1 calls to 1 put
-
Hims House podcast shares statement from Hims & Hers regarding Bloomberg report
-
After-hours movers: UnitedHealth, Applied Materials, Intel, Hims & Hers Health
-
Hims & Hers Health, Inc. (HIMS) Probed By US FTC Over Cancellation Practices - Bloomberg
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1.6 calls to 1 put with a focus on August 55 calls
-
HIMS Shares Decline Amid Lower Revenue Per Order For GLP-1 Following Novo Nordisk Collaboration Termination, Securities Class Action Pending -- Hagens Berman
-
Popular stocks volume: HIMS INTC SNAP OPEN UNH SMCI RIVN HOOD COIN UBER MSTR PFE
-
Novo Nordisk files 14 new lawsuits over compounded semaglutide drugs
-
Hims & Hers Health, Inc. (HIMS) on Watch; Novo Nordisk (NVO) Expands Legal Action to Protect US Patients From Non-FDA-approved Compounded 'Semaglutide'
-
Popular stocks volume: HIMS HOOD PFE SMCI SOFI COIN
-
BTIG Reiterates Buy Rating on Hims and Hers (HIMS), PT $85

